Heike Niessner

2.9k total citations
56 papers, 1.1k citations indexed

About

Heike Niessner is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Heike Niessner has authored 56 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 28 papers in Oncology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Heike Niessner's work include Melanoma and MAPK Pathways (30 papers), Cutaneous Melanoma Detection and Management (13 papers) and CAR-T cell therapy research (10 papers). Heike Niessner is often cited by papers focused on Melanoma and MAPK Pathways (30 papers), Cutaneous Melanoma Detection and Management (13 papers) and CAR-T cell therapy research (10 papers). Heike Niessner collaborates with scholars based in Germany, Switzerland and United States. Heike Niessner's co-authors include Tobias Sinnberg, Claus Garbe, Friedegund Meier, Teresa Amaral, Birgit Schittek, Mitchell P. Levesque, Christian Busch, Clemens Krepler, Sascha Venturelli and Andrea Forschner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Heike Niessner

53 papers receiving 1.1k citations

Peers

Countries citing papers authored by Heike Niessner

Since Specialization

Citations

This map shows the geographic impact of Heike Niessner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heike Niessner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heike Niessner more than expected).

Fields of papers citing papers by Heike Niessner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heike Niessner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heike Niessner. The network helps show where Heike Niessner may publish in the future.

Co-authorship network of co-authors of Heike Niessner

This figure shows the co-authorship network connecting the top 25 collaborators of Heike Niessner. A scholar is included among the top collaborators of Heike Niessner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heike Niessner. Heike Niessner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma 2025 ·International Journal of Molecular Sciences ·Corinna Kosnopfel, Tobias Sinnberg, (unknown), (unknown), Claus Garbe, Heike Niessner	0
2	Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 451 patients (pts) with stage I/II melanoma who did not undergo sentinel lymph node biopsy. 2024 ·Journal of Clinical Oncology ·Teresa Amaral, (unknown), (unknown), (unknown), Tobias Sinnberg, Heike Niessner, (unknown), Tim Arentsen, Christian Groß, Alexander M.M. Eggermont, Ulrike Leiter, Lukas Flatz, Stephan Forchhammer	1
3	BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms 2023 ·International Journal of Cancer ·(unknown), (unknown), Alexander Schulz, Alexander Arthur Wurm, (unknown), Mildred Sergon, Antje Tunger, Mathias Lesche, Rebekka Wehner, Anja Müller, (unknown), Heike Niessner, Andreas Dahl, Stefan Beissert, Marc Schmitz, Friedegund Meier, Barbara Seliger, Dana Westphal	5
4	PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo 2023 ·Cancer Research Communications ·(unknown), Heike Niessner, Birgit Sauer, (unknown), (unknown), (unknown), Tobias Sinnberg, Birgit Schittek	8
5	Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma 2023 ·Cancers ·Heike Niessner, (unknown), Corinna Kosnopfel, Matthias Meinhardt, Dana Westphal, Friedegund Meier, Bastian Schilling, Tobias Sinnberg	1
6	Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion 2023 ·Journal of Experimental & Clinical Cancer Research ·Corinna Kosnopfel, (unknown), Heike Niessner, (unknown), Tobias Sinnberg, Angelika Hofmann, (unknown), David Schrama, (unknown), (unknown), Birgit Sauer, Aarthi Jayanthan, Georg Lenz, Sandra E. Dunn, Bastian Schilling, Birgit Schittek	9
7	Interim analysis of MelaRisk, a biomarker assay validation study in stage IB/IIA melanoma tissue. 2023 ·Journal of Clinical Oncology ·Stephan Forchhammer, (unknown), Tobias Sinnberg, Heike Niessner, Ulrike Leiter, Ulrike Keim, Andrea Forschner, Claus Garbe, Lukas Flatz, Teresa Amaral	1
8	EGFR expression and relapse in patients with melanoma receiving adjuvant PD-1-based immunotherapy. 2023 ·Journal of Clinical Oncology ·Teresa Amaral, Oltin T. Pop, (unknown), Tobias Sinnberg, Heike Niessner, (unknown), Markus Joerger, Christopher Schroeder, Sorin Armeanu–Ebinger, Antonio Cozzio, Ulrike Leiter, Wolfram Jochum, Stephan Forchhammer, Mitchell P. Levesque, Joanna Mangana, Michael Hölzel, Reinhard Dummer, Christian M. Schürch, Andrea Forschner, Lukas Flatz	1
9	Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy 2021 ·Cancers ·(unknown), Tobias Sinnberg, Heike Niessner, Andrea Forschner, Claus Garbe, Boris Maček, Nicolas Nalpas	3
10	Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos? 2020 ·Cancers ·(unknown), (unknown), Claus Garbe, Heike Niessner, Tobias Sinnberg	39
11	Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients 2020 ·Cancers ·Franz J. Hilke, Tobias Sinnberg, (unknown), Heike Niessner, German Demidov, Teresa Amaral, Stephan Ossowski, Irina Bonzheim, Martin Röcken, Olaf Rieß, Claus Garbe, Christopher Schroeder, Andrea Forschner	37
12	Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion 2020 ·Cancers ·Corinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, Heike Niessner, (unknown), Birgit Fehrenbacher, Martin Schaller, Peter R. Mertens, Claus Garbe, Basant Kumar Thakur, Birgit Schittek	18
13	Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM). 2019 ·Journal of Clinical Oncology ·Claus Garbe, Tobias Sinnberg, Heike Niessner, Heiko Sülberg, Thomas Eigentler, Teresa Amaral	1
14	6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells 2018 ·Cellular Physiology and Biochemistry ·Sascha Venturelli, Heike Niessner, Tobias Sinnberg, Alexander Berger, Markus Burkard, (unknown), (unknown), Alexander Böcker, Christian Leischner, Herbert Riepl, Jan Frank, Ulrich M. Lauer, Claus Garbe, Christian Busch	27
15	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma 2017 ·Clinical Cancer Research ·Heike Niessner, Tobias Sinnberg, Corinna Kosnopfel, Keiran S.M. Smalley, Daniela Beck, Christian Praetorius, (unknown), Stefan Beissert, Dagmar Kulms, Martin Schaller, Claus Garbe, Keith T. Flaherty, Dana Westphal, Ines Wanke, Friedegund Meier	34
16	The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition 2017 ·European Journal of Cancer ·Teresa Amaral, Tobias Sinnberg, Friedegund Meier, Clemens Krepler, Mitchell P. Levesque, Heike Niessner, Claus Garbe	92
17	A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib 2016 ·EBioMedicine ·Tobias Sinnberg, (unknown), (unknown), Ana Velić, Boris Maček, Ulrich Rothbauer, (unknown), Oliver Pötz, Stefan Czemmel, Heike Niessner, Friedegund Meier, Kristian Ikenberg, Claus Garbe, Birgit Schittek	40
18	Molecular mechanisms of pharmacological doses of ascorbate on cancer cells 2015 ·Wiener Medizinische Wochenschrift ·Sascha Venturelli, Tobias Sinnberg, Heike Niessner, Christian Busch	20
19	Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells 2014 ·Frontiers in Oncology ·Sascha Venturelli, Tobias Sinnberg, Alexander Berger, Seema Noor, Mitchell P. Levesque, (unknown), Heike Niessner, Ulrich M. Lauer, Michael Bitzer, Claus Garbe, Christian Busch	35
20	Cytotoxicity of new duplex drugs linking 3′‐C‐ethynylcytidine and 5‐fluor‐2′‐deoxyuridine against human melanoma cells 2012 ·International Journal of Cancer ·Sarah Schott, Heike Niessner, Tobias Sinnberg, Sascha Venturelli, Alexander Berger, Kristian Ikenberg, Jessie Villanueva, Friedegund Meier, Claus Garbe, Christian Busch	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact